Ensol Biosciences Inc.
AI-driven biopharma developing peptide drugs for unmet medical needs.
140610 | KO
Overview
Corporate Details
- ISIN(s):
- KR7140610007
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 테크노10로 51(탑립동), 대전광역시
- Website:
- https://www.ensolbio.co.kr/eng/
- Sector:
- Manufacturing
Description
Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-13 00:00 |
주요사항보고서(전환사채권발행결정)
|
Korean | 49.2 KB | ||
| 2024-08-08 00:00 |
[기재정정]기타주요경영사항(자율공시) (퇴행성디스크질환 치료제 P2K의 적응증 확대 기술이전 계약체결)
|
Korean | 14.1 KB | ||
| 2024-07-05 00:00 |
기타주요경영사항(자율공시) (퇴행성디스크질환 치료제 P2K의 적응증 확대 기술이전 계약체결)
|
Korean | 6.7 KB | ||
| 2024-06-19 00:00 |
임상시험단계진입ㆍ종료(자율공시)
|
Korean | 16.4 KB | ||
| 2024-06-10 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 8.8 KB | ||
| 2024-05-28 00:00 |
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2024-04-24 00:00 |
기업설명회(IR)개최
|
Korean | 7.2 KB | ||
| 2024-03-29 00:00 |
사업보고서 (2023.12)
|
Korean | 471.3 KB | ||
| 2024-03-28 00:00 |
주식매수선택권부여에관한신고
|
Korean | 13.7 KB | ||
| 2024-03-28 00:00 |
정기주주총회결과
|
Korean | 19.9 KB | ||
| 2024-03-27 00:00 |
감사보고서제출
|
Korean | 9.4 KB | ||
| 2024-03-20 00:00 |
기타주요경영사항(자율공시) (감사보고서 제출 지연)
|
Korean | 4.9 KB | ||
| 2024-03-13 00:00 |
주주총회소집결의
|
Korean | 12.4 KB | ||
| 2024-03-13 00:00 |
주주총회소집공고
|
Korean | 74.4 KB | ||
| 2024-03-08 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 91.5 KB |
Automate Your Workflow. Get a real-time feed of all Ensol Biosciences Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ensol Biosciences Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ensol Biosciences Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
